EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The ketamine metabolite ( 2R,6R )‐hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer's disease

Felipe C Ribeiro, Danielle Cozachenco, Elentina K Argyrousi, Agnieszka Staniszewski, Shane Wiebe, Joao D Calixtro, Rubens Soares-Neto, Aycheh Al-Chami, Fatema El Sayegh, Sara Bermudez, Emily Arsenault, Marcelo Cossenza und 9 weitere

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.14034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Felipe C Ribeiro und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Alzheimer Disease, Ketamine, Hippocampus, Disease Models, Animal. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: International Brain Research Organization, Serrapilheira Institute, Instituto Nacional Saúde Cerebral.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Impaired brain protein synthesis, synaptic plasticity, and memory are major hallmarks of Alzheimer's disease (AD). The ketamine metabolite ( 2R,6R )‐hydroxynorketamine (HNK) has been shown to modulate protein synthesis, but its effects on memory in AD models remain elusive. METHODS We investigated the effects of HNK on hippocampal protein synthesis, long‐term potentiation (LTP), and memory in AD mouse models. RESULTS HNK activated extracellular signal‐regulated kinase 1/2 (ERK1/2), mechanistic target of rapamycin (mTOR), and p70S6 kinase 1 (S6K1)/ribosomal protein S6 signaling pathways. Treatment with HNK rescued hippocampal LTP and memory deficits in amyloid‐β oligomers (AβO)‐infused mice in an ERK1/2‐dependent manner. Treatment with HNK further corrected aberrant transcription, LTP and memory in aged APP/PS1 mice. DISCUSSION Our findings demonstrate that HNK induces signaling and transcriptional responses that correct synaptic and memory deficits in AD mice. These results raise the prospect that HNK could serve as a therapeutic approach in AD. Highlights The ketamine metabolite HNK activates hippocampal ERK/mTOR/S6 signaling pathways. HNK corrects hippocampal synaptic and memory defects in two mouse models of AD. Rescue of synaptic and memory impairments by HNK depends on ERK signaling. HNK corrects aberrant transcriptional signatures in APP/PS1 mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseKetamineHippocampusDisease Models, AnimalMice, TransgenicNeuronal PlasticityAnimalsMiceLong-Term PotentiationAmyloid beta-PeptidesProtein BiosynthesisTOR Serine-Threonine KinasesRNA, MessengerMemoryMaleMemory DisordersMice, Inbred C57BLAmyloid beta-Protein PrecursorPresenilin-1Humans

Stichwörter der Autor:innen

Alzheimer's diseasehydroxynorketaminemRNA translationmemorysynaptic plasticity

Substanzen

KetamineAmyloid beta-Peptides6-hydroxynorketamineTOR Serine-Threonine KinasesRNA, MessengerAmyloid beta-Protein PrecursorPresenilin-1

Autor:innen und Institutionen

  • Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
  • Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
  • Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
  • Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada.
  • Department of Physiology and Pharmacology, Fluminense Federal University, Biomedical Institute, Niterói, Rio de Janeiro, Brazil.
  • Department of Neurosciences, Université de Montréal, Centre for Interdisciplinary Research on Brain and Learning and Research Group on Neural Signaling and Circuits, Montreal, Quebec, Canada.

Förderung

  • International Brain Research Organization
  • Serrapilheira Institute
  • Instituto Nacional Saúde Cerebral
  • National Institute of Translational Neuroscience
  • Alzheimer's Association
  • Alzheimer's Society Canada
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Blas Frangione Early Career Achievement Award

Zitieren

APA

Ribeiro, F. C., Cozachenco, D., Argyrousi, E. K., Staniszewski, A., Wiebe, S., Calixtro, J. D., Soares-Neto, R., Al-Chami, A., Sayegh, F. E., Bermudez, S., Arsenault, E., Cossenza, M., Lacaille, J. C., Nader, K., Sun, H., De Felice, F. G., Lourenco, M. V., Arancio, O., Aguilar-Valles, A., …, & Ferreira, S. T. (2024). The ketamine metabolite ( 2R,6R )‐hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14034

Vancouver

Ribeiro FC, Cozachenco D, Argyrousi EK, Staniszewski A, Wiebe S, Calixtro JD, et al. The ketamine metabolite ( 2R,6R )‐hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer's disease. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14034

BibTeX
@article{Ribeiro2024,
  author = {Ribeiro, Felipe C and Cozachenco, Danielle and Argyrousi, Elentina K and Staniszewski, Agnieszka and Wiebe, Shane and Calixtro, Joao D and Soares-Neto, Rubens and Al-Chami, Aycheh and Sayegh, Fatema El and Bermudez, Sara and Arsenault, Emily and Cossenza, Marcelo and Lacaille, Jean-Claude and Nader, Karim and Sun, Hongyu and De Felice, Fernanda G and Lourenco, Mychael V and Arancio, Ottavio and Aguilar-Valles, Argel and Sonenberg, Nahum and Ferreira, Sergio T},
  title = {The ketamine metabolite ( 2R,6R )‐hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.14034}
}
Kostenlos starten →